Interim CEO Shift And Strategy Review Drive Kenvue's Turnaround Efforts

Kenvue Inc. (NYSE:KVUE) is one of the 10 Stocks with Huge Catalysts on the Horizon.

The company names an interim CEO and launches a strategic review as sales decline, sparking investor pressure.

Based in New Jersey, Kenvue Inc. (NYSE:KVUE) is a global consumer health leader. Operating in over 165 countries, the company serves more than 1.2 billion people. Its portfolio includes iconic brands such as Tylenol, Neutrogena, Listerine, and Aveeno that have gained the trust of consumers and healthcare professionals spanning retail, pharmacy, and digital health channels in key markets like North America, Europe, and Asia.

Kenvue Inc. (NYSE:KVUE) is undergoing a major leadership transition and undertaking strategic changes to address underperformance and unlock shareholder value. The company appointed Kirk Perry as interim CEO in July 2025. Along with this decision, it is reviewing brand divestitures and execution strategies after a 4.2% organic sales decline in preliminary Q2 2025 results.

The review is targeted towards portfolio optimization and operational efficiency, amid activist investor pressure and an equity valuation gap versus peers. Potential brand sales, including those of Clean & Clear and Dr.Ci:Labo, could streamline operations. With full Q2 earnings expected on August 7, the change in CEO and strategic decisions could potentially shape market expectations.

Investor confidence in the stock remains high, with 52 hedge fund holders, as recorded by Insider Monkey, holding ownership in the company.

While we acknowledge the potential of KVUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Long Term Low Risk Stocks to Invest in and 13 Best Low Risk High Growth Stocks to Buy

Disclosure. None.